Akero Therapeutics IncNASDAQ:AKRO
- LAST PRICE19.9200
- TODAY'S CHANGE (%)-0.8100 (-3.9074%)
- Bid / Lots18.8000/ 1
- Ask / Lots20.7500/ 1
- Open / Previous Close20.7900 / 20.7300
- Day Range
- 52 Week Range
- Volume457,666
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKRO |
|---|---|---|
| 09:32 ET | 13393 | 20.815 |
| 09:34 ET | 1026 | 20.51 |
| 09:36 ET | 400 | 20.31 |
| 09:39 ET | 600 | 20.35 |
| 09:41 ET | 3075 | 20.37 |
| 09:43 ET | 200 | 20.475 |
| 09:48 ET | 700 | 20.5 |
| 09:50 ET | 2273 | 20.5 |
| 09:52 ET | 100 | 20.45 |
| 09:54 ET | 200 | 20.41 |
| 09:56 ET | 100 | 20.41 |
| 09:57 ET | 100 | 20.43 |
| 09:59 ET | 200 | 20.59 |
| 10:03 ET | 1600 | 20.49 |
| 10:06 ET | 700 | 20.47 |
| 10:08 ET | 100 | 20.58 |
| 10:10 ET | 11115 | 20.42 |
| 10:12 ET | 100 | 20.46 |
| 10:15 ET | 737 | 20.46 |
| 10:19 ET | 100 | 20.34 |
| 10:26 ET | 400 | 20.37 |
| 10:28 ET | 700 | 20.4 |
| 10:30 ET | 600 | 20.43 |
| 10:32 ET | 200 | 20.46 |
| 10:33 ET | 100 | 20.42 |
| 10:37 ET | 1324 | 20.41 |
| 10:39 ET | 100 | 20.39 |
| 10:44 ET | 730 | 20.38 |
| 10:48 ET | 100 | 20.39 |
| 10:50 ET | 500 | 20.37 |
| 10:51 ET | 1300 | 20.42 |
| 11:00 ET | 500 | 20.39 |
| 11:02 ET | 200 | 20.37 |
| 11:04 ET | 100 | 20.36 |
| 11:06 ET | 200 | 20.35 |
| 11:08 ET | 300 | 20.34 |
| 11:09 ET | 200 | 20.34 |
| 11:11 ET | 300 | 20.3 |
| 11:13 ET | 610 | 20.33 |
| 11:15 ET | 400 | 20.32 |
| 11:18 ET | 300 | 20.32 |
| 11:20 ET | 1000 | 20.3546 |
| 11:22 ET | 700 | 20.35 |
| 11:24 ET | 394 | 20.34 |
| 11:26 ET | 450 | 20.36 |
| 11:27 ET | 221 | 20.36 |
| 11:29 ET | 1378 | 20.305 |
| 11:31 ET | 300 | 20.29 |
| 11:33 ET | 200 | 20.285 |
| 11:36 ET | 334 | 20.2757 |
| 11:38 ET | 300 | 20.3 |
| 11:40 ET | 5463 | 20.23 |
| 11:42 ET | 195 | 20.2064 |
| 11:49 ET | 300 | 20.14 |
| 11:51 ET | 3300 | 20.075 |
| 11:54 ET | 322 | 20.03 |
| 11:56 ET | 1371 | 20.05 |
| 12:02 ET | 900 | 20.08 |
| 12:05 ET | 2830 | 20.06 |
| 12:12 ET | 1200 | 20.085 |
| 12:14 ET | 923 | 20.09 |
| 12:18 ET | 100 | 20.1094 |
| 12:20 ET | 1520 | 20.11 |
| 12:21 ET | 700 | 20.07 |
| 12:23 ET | 100 | 20.095 |
| 12:25 ET | 226 | 20.12 |
| 12:32 ET | 100 | 20.09 |
| 12:36 ET | 812 | 20.14 |
| 12:38 ET | 100 | 20.16 |
| 12:39 ET | 1293 | 20.16 |
| 12:43 ET | 100 | 20.15 |
| 12:45 ET | 1123 | 20.1326 |
| 12:50 ET | 500 | 20.12 |
| 12:52 ET | 1548 | 20.14 |
| 12:54 ET | 536 | 20.1109 |
| 12:57 ET | 200 | 20.095 |
| 01:03 ET | 300 | 20.1 |
| 01:08 ET | 100 | 20.07 |
| 01:10 ET | 800 | 20.1 |
| 01:14 ET | 500 | 20.1 |
| 01:17 ET | 200 | 20.13 |
| 01:21 ET | 1183 | 20.08 |
| 01:24 ET | 5201 | 20 |
| 01:28 ET | 518 | 19.97 |
| 01:33 ET | 236 | 19.95 |
| 01:35 ET | 200 | 19.93 |
| 01:37 ET | 3161 | 19.91 |
| 01:39 ET | 174 | 19.91 |
| 01:42 ET | 9525 | 19.94 |
| 01:44 ET | 229 | 19.94 |
| 01:46 ET | 902 | 19.98 |
| 01:51 ET | 1336 | 20 |
| 01:53 ET | 500 | 19.96 |
| 01:55 ET | 227 | 19.97 |
| 02:00 ET | 100 | 19.94 |
| 02:02 ET | 100 | 19.88 |
| 02:04 ET | 100 | 19.88 |
| 02:08 ET | 200 | 19.84 |
| 02:11 ET | 100 | 19.83 |
| 02:13 ET | 300 | 19.81 |
| 02:15 ET | 3100 | 19.81 |
| 02:18 ET | 100 | 19.81 |
| 02:20 ET | 700 | 19.83 |
| 02:22 ET | 200 | 19.81 |
| 02:24 ET | 500 | 19.81 |
| 02:26 ET | 800 | 19.83 |
| 02:27 ET | 600 | 19.82 |
| 02:29 ET | 500 | 19.85 |
| 02:31 ET | 601 | 19.84 |
| 02:36 ET | 400 | 19.825 |
| 02:38 ET | 1119 | 19.8439 |
| 02:40 ET | 930 | 19.8854 |
| 02:42 ET | 100 | 19.875 |
| 02:44 ET | 100 | 19.86 |
| 02:45 ET | 100 | 19.83 |
| 02:47 ET | 100 | 19.83 |
| 02:49 ET | 1200 | 19.83 |
| 02:54 ET | 700 | 19.84 |
| 02:56 ET | 500 | 19.885 |
| 02:58 ET | 800 | 19.89 |
| 03:00 ET | 600 | 19.855 |
| 03:02 ET | 801 | 19.84 |
| 03:03 ET | 639 | 19.84 |
| 03:09 ET | 1700 | 19.87 |
| 03:12 ET | 1061 | 19.93 |
| 03:14 ET | 813 | 19.94 |
| 03:16 ET | 329 | 19.91 |
| 03:18 ET | 300 | 19.885 |
| 03:20 ET | 100 | 19.885 |
| 03:21 ET | 900 | 19.93 |
| 03:23 ET | 524 | 19.93 |
| 03:25 ET | 4149 | 19.87 |
| 03:27 ET | 3738 | 19.87 |
| 03:30 ET | 200 | 19.85 |
| 03:32 ET | 137 | 19.85 |
| 03:34 ET | 736 | 19.86 |
| 03:36 ET | 200 | 19.85 |
| 03:38 ET | 4518 | 19.85 |
| 03:39 ET | 600 | 19.81 |
| 03:41 ET | 2127 | 19.81 |
| 03:43 ET | 1263 | 19.8308 |
| 03:45 ET | 1038 | 19.83 |
| 03:48 ET | 1324 | 19.945 |
| 03:50 ET | 624 | 19.93 |
| 03:52 ET | 4153 | 19.925 |
| 03:54 ET | 2592 | 19.95 |
| 03:56 ET | 4592 | 19.895 |
| 03:57 ET | 6003 | 19.95 |
| 03:59 ET | 158003 | 19.92 |
Yesterday
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO, from 17 hours ago by Dow Jones
17 hours ago by Dow JonesClass Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc., from 20 hours ago by Dow Jones
20 hours ago by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO, from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
May 17, 2024
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO, from 10:45PM ET on Friday May 17, 2024 by Dow Jones
10:45PM ET on Friday May 17, 2024 by Dow JonesROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- AKRO, from 7:46PM ET on Friday May 17, 2024 by Dow Jones
7:46PM ET on Friday May 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akero Therapeutics Inc | 1.4B | -6.2x | --- |
Belite Bio Inc | 1.4B | -38.2x | --- |
Day One Biopharmaceuticals Inc | 1.4B | -6.5x | --- |
Cullinan Therapeutics Inc | 1.3B | -6.3x | --- |
Morphic Holding Inc | 1.5B | -8.4x | --- |
Spyre Therapeutics Inc | 1.5B | -0.5x | --- |
Company Information
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Contact Information
- Headquarters
- 601 Gateway Boulevard, Suite 350SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-487-6488
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- President, Chief Executive Officer, Director
- Andrew Cheng
- Co-Founder, Chief Operating Officer, Executive Vice President, Secretary
- Jonathan Young
- Co-Founder, Chief Scientific Officer
- Timothy Rolph
- Chief Financial Officer, Executive Vice President, Head of Corporate Development, Treasurer
- William White
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 69.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.30 |
EPS | $-3.20 |
Book Value | $9.60 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
